

- Horton, J. D., Goldstein, J. L., & Brown, M. S. (2002). SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. *Journal of Clinical Investigation*, 109(9), 1125-1131.
- Huang, E. S., Brown, S. E., Ewigman, B. G., Foley, E. C., & Meltzer, D. O. (2007). Patient perceptions of quality of life with diabetes-related complications and treatments. *Diabetes care*, 30(10), 2478-2483.
- Jacobsen, W., Kuhn, B., Soldner, A., Kirchner, G., Sewing, K. F., Kollman, P. A., & Christians, U. (2000). Lactonization is the critical first step in the disposition of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor atorvastatin. *Drug metabolism and disposition*, 28(11), 1369-1378.
- Jönsson, B., Johannesson, M., Kjekshus, J., Olsson, A. G., Pedersen, T. R., & Wedel, H. (1996). Cost-effectiveness of cholesterol lowering Results from the Scandinavian Simvastatin Survival Study (4S). *European heart journal*, 17(7), 1001-1007.
- Jukema, J. W., & van der Hoorn, J. W. (2004). Amlodipine and atorvastatin in atherosclerosis: a review of the potential of combination therapy. *Expert opinion on pharmacotherapy*, 5(2), 459-468.
- Jukema, J. W., van Boven, A. J., Zwinderman, A. H., Van der Laarse, A., & Bruschke, A. V. (1998). Proposed synergistic effect of calcium channel blockers with lipid-lowering therapy in retarding progression of coronary atherosclerosis. *Cardiovascular drugs and therapy*, 12(1), 111-118.